TY - JOUR
T1 - Paraoxonase 1 and atherosclerosis-related diseases
AU - Kotur-Stevuljević, Jelena
AU - Vekić, Jelena
AU - Stefanović, Aleksandra
AU - Zeljković, Aleksandra
AU - Ninić, Ana
AU - Ivanišević, Jasmina
AU - Miljković, Milica
AU - Sopić, Miron
AU - Munjas, Jelena
AU - Mihajlović, Marija
AU - Spasić, Slavica
AU - Jelić-Ivanović, Zorana
AU - Spasojević-Kalimanovska, Vesna
N1 - Publisher Copyright:
© 2019 International Union of Biochemistry and Molecular Biology
PY - 2020/3/1
Y1 - 2020/3/1
N2 - A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.
AB - A direct and an indirect relationship between paraoxonase 1 (PON1) and atherosclerosis exists. Given PON1's physical location within high-density lipoprotein (HDL) particles and its recognized enzyme activity, it is certainly reasonable to suggest that PON1 facilitates the antiatherogenic nature of HDL particles. PON1 also plays a role in regulating reverse cholesterol transport, antioxidative, anti-inflammatory, antiapoptotic, vasodilative, and antithrombotic activities and several endothelial cell functions. HDL dysfunctionality is a more recent issue and seems to be centered on pathological conditions affecting HDL structure and size profiles. This review is focused on the role of PON1 status in different atherosclerosis-related diseases that we have studied over the last twenty years (coronary heart disease, acute ischemic stroke, diabetes mellitus type 2, end-stage renal disease, chronic obstructive pulmonary disease, and sarcoidosis) with the aim to determine the true value of PON1 as a biomarker. The role of PON1 in cancer is also covered, as risk factors and mechanisms underlying both atherosclerosis and cancer share common features.
KW - HDL dysfunction
KW - atherosclerosis
KW - cancer
KW - cardiovascular disease
KW - diabetes
KW - paraoxonase 1
KW - renal disease
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85070335419&partnerID=8YFLogxK
U2 - 10.1002/biof.1549
DO - 10.1002/biof.1549
M3 - Review article
C2 - 31400246
AN - SCOPUS:85070335419
SN - 0951-6433
VL - 46
SP - 193
EP - 205
JO - BioFactors
JF - BioFactors
IS - 2
ER -